Skip to content

Significance of ICG fluorescence-guided navigation surgery

Significance of ICG fluorescence-guided navigation laparoscopic surgery for gastric and esophagogastric junction cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031210135
Enrollment
150
Registered
2021-06-09
Start date
2021-06-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer, Esophagogastric junction cancer Gastric cancer, Esophagogastric junction cancer

Interventions

Endoscopic submucosal injection of ICG around tumor.
ICG, gastric cancer, esophagogastric junction cancer

Sponsors

Sano Akihiko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with resectable gastric and esophagogastric junction cancer who have pathologically diagnosed of adenocarcinoma. 2. 20-years old and more, PS 0-2. Gender does not matter. 3. Consent to participate in the study and the patient or his / her representative has signed the ethics committee approval consent document.

Exclusion criteria

Exclusion criteria: 1. Patients with active double cancer (simultaneous double cancer and metachronous double cancer with a disease-free period of up to 5 years). 2. Patients with a history of frequent laparotomy and expected to have a high degree of intra-abdominal adhesions. 3. Patients with a history of ICG or iodine hypersensitivity, asthma or severe drug allergies. 4. Patients with serious comorbidities. 5. Female patients of childbearing potential or breastfeeding. 6. Patients receiving continuous systemic steroids (oral or intravenous). 7. Patients with mental illness or psychiatric symptoms who are judged to be difficult to participate. 8. In addition, patients who are judged by the principal investigator to be inappropriate for participation in this study.

Design outcomes

Primary

MeasureTime frame
Number of dissected lymph nodes.

Secondary

MeasureTime frame
Operation time, estimated blood loss, postoperative complication rate of Grade 3 or higher according to Clavien-Dindo classification, postoperative inflammatory findings (WBC/CRP), postoperative hospital stay, Number of pathological metastatic lymph nodes with ICG-positive dissected lymph nodes, Rate of pathological metastasis of ICG-fluorescent lymph nodes, Overall survival rate, Cancer-specific survival rate

Contacts

Public ContactAkihiko Sano

Gunma University Hospital

ak_sano@gunma-u.ac.jp+81-27-220-8224

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026